Real World, Pharmacy-assessed Adherence to New Onset Entresto® (Sacubitril/Valsartan) in Patients With Chronic Heart Failure (LOCATE-HF)

Novartis

Status: Withdrawn

Conditions: Heart Failure

Treatments: Other: sacubitril/valsartan

Study type: Observational

Funder types: Industry

Identifiers

NCT05870709

CLCZ696BDE05

Details and patient eligibility

About

This is a multicenter, non-interventional, single arm cohort study with prospective collection of primary data via pharmacists in community pharmacies to describe adherence to sacubitril/valsartan in study patients at the end of the study. Eligible patients with newly prescribed sacubitril/valsartan will be observed in pharmaceutical routine.

Full description

The study duration will last up to about 30 weeks per patient and will consist of a approximately three visits - Baseline visit (V1), week 1-12 (V2) and week 13-30 (V3).

No exact date for visit 2 and visit 3 will be enforced, to avoid interference with usual care.

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients with first ambulatory sacubitril/valsartan prescription at screening
2. Internet enabled device / smartphone (patient or affiliate)
3. ≥ 18 years of age
4. Written informed consent to participate in the study

Exclusion criteria

1. Depression-related medication, depression-related comorbidities (patient-reported)
2. Patients with unstable acute complications or with an advanced illness likely to interfere with participation in this trial as judged by the enrolling pharmacist
3. Simultaneous participation in any interventional trial or simultaneous participation in another Novartis-sponsored non-interventional study with sacubitril/valsartan

Trial design

0 participants in 1 patient group

sacubitril/valsartan

Description:

patient with a first ambulatory sacubitril/valsartan prescription

Treatment:

Other: sacubitril/valsartan